AVLN
Avalyn Pharma Inc.
Price Chart
Latest Quote
$30.68
+2.61 (+9.30%)
Current Price
| Previous Close | $28.07 |
| Open | $28.02 |
| Day High | $31.14 |
| Day Low | $28.00 |
| Volume | 219,528 |
Stock Information
| Shares Outstanding | 44.33M |
| Net Income | $-85.20M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.36B |
| EPS (TTM) | $-2.26 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Income | $-85.20M |
| Book/sh | $-10.11 |
| Employees | 50 |
Financial Ratios
| Quick Ratio | 9.86 |
| Current Ratio | 10.19 |
Returns & Margins
| ROA | -41.74% |
| ROE | -68.34% |
Ownership
| Institutional Ownership | 49.91% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -16.15 |
| P/B | -3.04 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $59.00 |
Technical Indicators
| SMA20 | $27.99 |
| RSI | 58.40 |
| ATR | 2.7843 |
| Shares Float | 14.45M |
| Short Float | 2.02% |
| Short Ratio | 1.37 |
| Rel Volume | 0.84 |
Performance History
| Week | +7.54% |
| Month | +15.21% |
| YTD | +4.04% |
| 10 Years | +4.04% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $30.68 | 219,528 |
| 2026-06-16 | $28.07 | 383,900 |
| 2026-06-15 | $28.75 | 275,600 |
| 2026-06-12 | $30.08 | 286,500 |
| 2026-06-11 | $28.07 | 199,600 |
| 2026-06-10 | $28.53 | 342,800 |
| 2026-06-09 | $28.67 | 200,700 |
| 2026-06-08 | $28.06 | 272,300 |
| 2026-06-05 | $27.06 | 327,000 |
| 2026-06-04 | $26.99 | 216,000 |
| 2026-06-03 | $26.40 | 206,400 |
| 2026-06-02 | $25.72 | 150,000 |
| 2026-06-01 | $26.66 | 155,800 |
| 2026-05-29 | $28.78 | 268,100 |
| 2026-05-28 | $28.39 | 395,000 |
| 2026-05-27 | $26.82 | 213,200 |
| 2026-05-26 | $26.70 | 367,800 |
| 2026-05-22 | $28.84 | 321,500 |
| 2026-05-21 | $28.41 | 240,500 |
| 2026-05-20 | $28.03 | 181,000 |
| 2026-05-19 | $28.11 | 126,100 |
| 2026-05-18 | $26.63 | 430,000 |
About Avalyn Pharma Inc.
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts.
đ° Latest News
Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead
MarketBeat âĸ 2026-06-06T02:06:10Z
Assessing Avalyn Pharma (AVLN) Valuation As Investors React To Recent Share Price Moves
Simply Wall St. âĸ 2026-06-01T20:08:29Z
Is Avalyn Pharma (NASDAQ:AVLN) In A Good Position To Invest In Growth?
Simply Wall St. âĸ 2026-04-30T18:09:06Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | ||
| Total Revenue | $0 | $0 |
| Operating Revenue | $0 | $0 |
| Expenses | ||
| Total Expenses | $91,292,000 | $57,121,000 |
| Other Income Expense | $-89,000 | $-62,000 |
| Other Non Operating Income Expenses | $-89,000 | $-62,000 |
| Net Non Operating Interest Income Expense | $6,177,000 | $7,439,000 |
| Operating Expense | $91,292,000 | $57,121,000 |
| General And Administrative Expense | $14,678,000 | $11,362,000 |
| Income & Earnings | ||
| Net Income From Continuing Operation Net Minority Interest | $-85,204,000 | $-49,744,000 |
| Net Interest Income | $6,177,000 | $7,439,000 |
| Interest Income | $6,177,000 | $7,439,000 |
| Normalized Income | $-85,204,000 | $-49,744,000 |
| Net Income From Continuing And Discontinued Operation | $-85,204,000 | $-49,744,000 |
| Total Operating Income As Reported | $-91,292,000 | $-57,121,000 |
| Net Income Common Stockholders | $-85,204,000 | $-49,744,000 |
| Net Income | $-85,204,000 | $-49,744,000 |
| Net Income Including Noncontrolling Interests | $-85,204,000 | $-49,744,000 |
| Net Income Continuous Operations | $-85,204,000 | $-49,744,000 |
| Pretax Income | $-85,204,000 | $-49,744,000 |
| Interest Income Non Operating | $6,177,000 | $7,439,000 |
| Operating Income | $-91,292,000 | $-57,121,000 |
| Per Share | ||
| Diluted EPS | $-2.04 | $-1.19 |
| Basic EPS | $-2.04 | $-1.19 |
| Other | ||
| Tax Effect Of Unusual Items | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-91,250,000 | $-57,092,000 |
| Reconciled Depreciation | $42,000 | $29,000 |
| EBITDA (Bullshit earnings) | $-91,250,000 | $-57,092,000 |
| EBIT | $-91,292,000 | $-57,121,000 |
| Diluted Average Shares | $41,812,047 | $41,812,047 |
| Basic Average Shares | $41,812,047 | $41,812,047 |
| Diluted NI Availto Com Stockholders | $-85,204,000 | $-49,744,000 |
| Research And Development | $76,614,000 | $45,759,000 |
| Selling General And Administration | $14,678,000 | $11,362,000 |
| Other Gand A | $6,059,000 | $6,027,000 |
| Salaries And Wages | $8,619,000 | $5,335,000 |
Fetched: 2026-06-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $-238,656,000 | $-174,522,000 |
| Total Assets | $148,881,000 | $124,519,000 |
| Total Non Current Assets | $5,321,000 | $10,132,000 |
| Other Non Current Assets | $2,999,000 | $2,549,000 |
| Investmentin Financial Assets | $0 | $7,489,000 |
| Current Assets | $143,560,000 | $114,387,000 |
| Prepaid Assets | $4,664,000 | $3,170,000 |
| Receivables | $537,000 | $591,000 |
| Accrued Interest Receivable | $537,000 | $591,000 |
| Cash Cash Equivalents And Short Term Investments | $138,359,000 | $110,626,000 |
| Cash And Cash Equivalents | $52,315,000 | $23,955,000 |
| Debt | ||
| Total Debt | $1,669,000 | $0 |
| Long Term Debt And Capital Lease Obligation | $1,225,000 | $0 |
| Current Debt And Capital Lease Obligation | $444,000 | - |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $387,537,000 | $299,041,000 |
| Total Non Current Liabilities Net Minority Interest | $373,446,000 | $290,297,000 |
| Current Liabilities | $14,091,000 | $8,744,000 |
| Payables And Accrued Expenses | $9,355,000 | $5,993,000 |
| Payables | $3,758,000 | $2,277,000 |
| Accounts Payable | $3,758,000 | $2,277,000 |
| Equity | ||
| Common Stock Equity | $-238,656,000 | $-174,522,000 |
| Total Equity Gross Minority Interest | $-238,656,000 | $-174,522,000 |
| Stockholders Equity | $-238,656,000 | $-174,522,000 |
| Gains Losses Not Affecting Retained Earnings | $134,000 | $202,000 |
| Other Equity Adjustments | $134,000 | $202,000 |
| Retained Earnings | $-265,362,000 | $-180,158,000 |
| Preferred Securities Outside Stock Equity | $372,221,000 | $290,297,000 |
| Other | ||
| Ordinary Shares Number | $41,812,047 | $41,812,047 |
| Share Issued | $41,812,047 | $41,812,047 |
| Tangible Book Value | $-238,656,000 | $-174,522,000 |
| Invested Capital | $-238,656,000 | $-174,522,000 |
| Working Capital | $129,469,000 | $105,643,000 |
| Capital Lease Obligations | $1,669,000 | $0 |
| Total Capitalization | $-238,656,000 | $-174,522,000 |
| Additional Paid In Capital | $26,548,000 | $5,429,000 |
| Capital Stock | $24,000 | $5,000 |
| Common Stock | $24,000 | $5,000 |
| Long Term Capital Lease Obligation | $1,225,000 | $0 |
| Current Capital Lease Obligation | $444,000 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,292,000 | $2,751,000 |
| Current Accrued Expenses | $5,597,000 | $3,716,000 |
| Investments And Advances | $0 | $7,489,000 |
| Net PPE | $2,322,000 | $94,000 |
| Accumulated Depreciation | $-54,000 | $-12,000 |
| Gross PPE | $2,376,000 | $106,000 |
| Construction In Progress | $682,000 | $0 |
| Other Properties | $1,540,000 | $10,000 |
| Machinery Furniture Equipment | $154,000 | $96,000 |
| Other Short Term Investments | $86,044,000 | $86,671,000 |
| Available For Sale Securities | - | $7,489,000 |
Fetched: 2026-06-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Free Cash Flow | ||
| Free Cash Flow | $-81,828,000 | $-48,463,000 |
| Operating Activities | ||
| Operating Cash Flow | $-81,484,000 | $-48,368,000 |
| Cash Flow From Continuing Operating Activities | $-81,484,000 | $-48,368,000 |
| Operating Gains Losses | - | $45,000 |
| Investing Activities | ||
| Capital Expenditure | $-344,000 | $-95,000 |
| Investing Cash Flow | $10,057,000 | $-91,474,000 |
| Cash Flow From Continuing Investing Activities | $10,057,000 | $-91,474,000 |
| Financing Activities | ||
| Issuance Of Capital Stock | $100,363,000 | $0 |
| Financing Cash Flow | $99,787,000 | $89,000 |
| Cash Flow From Continuing Financing Activities | $99,787,000 | $89,000 |
| Net Other Financing Charges | $-594,000 | $38,000 |
| Net Preferred Stock Issuance | $100,363,000 | $0 |
| Preferred Stock Issuance | $100,363,000 | $0 |
| Other | ||
| End Cash Position | $52,315,000 | $23,955,000 |
| Beginning Cash Position | $23,955,000 | $163,708,000 |
| Changes In Cash | $28,360,000 | $-139,753,000 |
| Proceeds From Stock Option Exercised | $18,000 | $51,000 |
| Net Investment Purchase And Sale | $10,401,000 | $-91,379,000 |
| Sale Of Investment | $119,700,000 | $40,000,000 |
| Purchase Of Investment | $-109,299,000 | $-131,379,000 |
| Net PPE Purchase And Sale | $-344,000 | $-95,000 |
| Purchase Of PPE | $-344,000 | $-95,000 |
| Change In Working Capital | $2,611,000 | $1,360,000 |
| Change In Other Current Liabilities | $-7,000 | $-4,057,000 |
| Change In Other Current Assets | $-450,000 | $-1,488,000 |
| Change In Payables And Accrued Expense | $4,253,000 | $3,510,000 |
| Change In Accrued Expense | $2,857,000 | $3,279,000 |
| Change In Payable | $1,396,000 | $231,000 |
| Change In Account Payable | $1,396,000 | $231,000 |
| Change In Prepaid Assets | $-1,185,000 | $3,395,000 |
| Other Non Cash Items | $146,000 | $50,000 |
| Stock Based Compensation | $3,274,000 | $2,471,000 |
| Amortization Of Securities | $-2,353,000 | $-2,579,000 |
| Depreciation Amortization Depletion | $42,000 | $29,000 |
| Depreciation And Amortization | $42,000 | $29,000 |
| Depreciation | $42,000 | $29,000 |
| Gain Loss On Sale Of PPE | $0 | $45,000 |
| Net Income From Continuing Operations | $-85,204,000 | $-49,744,000 |
Fetched: 2026-06-15